ys5 antibody
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 18, 2022 (NCT05245006)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Membrane cofactor proteinINHIBITOR
CD46 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05245006 | Phase 1 | Mar 18, 2022 | Department of Defense, Fortis Therapeutics, Inc., University of California, San Francisco |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2022 |
| Fortis Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1